New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars...
San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational...
SteinCares strengthens its role as the regional partner for global pharmaceutical companies seeking to bring innovative therapies to Latin American patients. Through this agreement, the company will continue to expand access to innovative, high-quality, and...
SteinCares enters Mexico—one of the most strategic pharmaceutical markets in Latin America—to expand its footprint and accelerate growth across the region. The partnership marks a major milestone in SteinCares’ regional expansion, underscoring its commitment to...
This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one of the world’s top-selling biologics—broadening access to specialty care for patients with chronic inflammatory diseases. The partnership...
